AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma
Conditions:   B-cell Malignancy;   Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma;   Waldenstrom Macroglobulinemia;   Mantle Cell Lymphoma;   Marginal Zone Lymphoma;   Follicular Lymphoma;   Non-Hodgkin Lymphoma Intervention:   Drug: AS-1763 Sponsor:   Carna Biosciences, Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 2, 2022 Category: Research Source Type: clinical trials